Sonesitatug vedotin granted priority review in the US for later-line treatment of patients
AZN•Sonesitatug vedotin was granted priority review in the US for second- and later-line treatment of patients with CLDN18.2-positive advanced gastric or GEJ cancers.
1. Priority review granted
Sonesitatug vedotin was granted priority review in the US for second- and later-line treatment of patients with CLDN18.2-positive advanced gastric or gastroesophageal junction (GEJ) cancers.




